QQQ   437.14 (+0.43%)
AAPL   180.75 (-0.37%)
MSFT   407.88 (+0.04%)
META   487.80 (+0.78%)
GOOGL   137.06 (+0.50%)
AMZN   174.65 (+0.86%)
TSLA   199.87 (-1.07%)
NVDA   791.14 (+1.87%)
NIO   5.64 (+3.87%)
AMD   186.56 (+5.68%)
BABA   74.20 (-0.52%)
T   17.00 (+0.24%)
F   12.43 (+1.06%)
MU   89.53 (-0.20%)
CGC   3.32 (-1.19%)
GE   156.12 (+0.33%)
DIS   111.32 (+0.47%)
AMC   4.43 (-11.22%)
PFE   26.89 (-0.55%)
PYPL   60.71 (+0.76%)
XOM   104.75 (+0.41%)
QQQ   437.14 (+0.43%)
AAPL   180.75 (-0.37%)
MSFT   407.88 (+0.04%)
META   487.80 (+0.78%)
GOOGL   137.06 (+0.50%)
AMZN   174.65 (+0.86%)
TSLA   199.87 (-1.07%)
NVDA   791.14 (+1.87%)
NIO   5.64 (+3.87%)
AMD   186.56 (+5.68%)
BABA   74.20 (-0.52%)
T   17.00 (+0.24%)
F   12.43 (+1.06%)
MU   89.53 (-0.20%)
CGC   3.32 (-1.19%)
GE   156.12 (+0.33%)
DIS   111.32 (+0.47%)
AMC   4.43 (-11.22%)
PFE   26.89 (-0.55%)
PYPL   60.71 (+0.76%)
XOM   104.75 (+0.41%)
QQQ   437.14 (+0.43%)
AAPL   180.75 (-0.37%)
MSFT   407.88 (+0.04%)
META   487.80 (+0.78%)
GOOGL   137.06 (+0.50%)
AMZN   174.65 (+0.86%)
TSLA   199.87 (-1.07%)
NVDA   791.14 (+1.87%)
NIO   5.64 (+3.87%)
AMD   186.56 (+5.68%)
BABA   74.20 (-0.52%)
T   17.00 (+0.24%)
F   12.43 (+1.06%)
MU   89.53 (-0.20%)
CGC   3.32 (-1.19%)
GE   156.12 (+0.33%)
DIS   111.32 (+0.47%)
AMC   4.43 (-11.22%)
PFE   26.89 (-0.55%)
PYPL   60.71 (+0.76%)
XOM   104.75 (+0.41%)
QQQ   437.14 (+0.43%)
AAPL   180.75 (-0.37%)
MSFT   407.88 (+0.04%)
META   487.80 (+0.78%)
GOOGL   137.06 (+0.50%)
AMZN   174.65 (+0.86%)
TSLA   199.87 (-1.07%)
NVDA   791.14 (+1.87%)
NIO   5.64 (+3.87%)
AMD   186.56 (+5.68%)
BABA   74.20 (-0.52%)
T   17.00 (+0.24%)
F   12.43 (+1.06%)
MU   89.53 (-0.20%)
CGC   3.32 (-1.19%)
GE   156.12 (+0.33%)
DIS   111.32 (+0.47%)
AMC   4.43 (-11.22%)
PFE   26.89 (-0.55%)
PYPL   60.71 (+0.76%)
XOM   104.75 (+0.41%)

Aptose Biosciences (APTO) Competitors

$1.83
-0.02 (-1.26%)
(As of 10:53 AM ET)

APTO vs. SRZN, FRLN, NKGN, ENTX, SABS, PLUR, INKT, INAB, ZIVO, and AIM

Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Surrozen (SRZN), Freeline Therapeutics (FRLN), NKGen Biotech (NKGN), Entera Bio (ENTX), SAB Biotherapeutics (SABS), Pluri (PLUR), MiNK Therapeutics (INKT), IN8bio (INAB), ZIVO Bioscience (ZIVO), and AIM ImmunoTech (AIM). These companies are all part of the "biological products, except diagnostic" industry.

Aptose Biosciences vs.

Aptose Biosciences (NASDAQ:APTO) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Surrozen's return on equity of -55.24% beat Aptose Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptose BiosciencesN/A -230.97% -142.96%
Surrozen N/A -55.24%-47.01%

1.1% of Aptose Biosciences shares are owned by institutional investors. Comparatively, 51.3% of Surrozen shares are owned by institutional investors. 9.5% of Aptose Biosciences shares are owned by company insiders. Comparatively, 35.0% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aptose Biosciences has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500.

Aptose Biosciences received 370 more outperform votes than Surrozen when rated by MarketBeat users. Likewise, 66.02% of users gave Aptose Biosciences an outperform vote while only 16.67% of users gave Surrozen an outperform vote.

CompanyUnderperformOutperform
Aptose BiosciencesOutperform Votes
373
66.02%
Underperform Votes
192
33.98%
SurrozenOutperform Votes
3
16.67%
Underperform Votes
15
83.33%

Aptose Biosciences currently has a consensus price target of $36.50, indicating a potential upside of 1,898.25%. Given Aptose Biosciences' higher probable upside, research analysts clearly believe Aptose Biosciences is more favorable than Surrozen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptose Biosciences
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Surrozen
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Surrozen has higher revenue and earnings than Aptose Biosciences. Surrozen is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/A-$41.82M-$7.93-0.23
Surrozen$12.50M2.20-$36M-$17.39-0.78

In the previous week, Aptose Biosciences had 2 more articles in the media than Surrozen. MarketBeat recorded 4 mentions for Aptose Biosciences and 2 mentions for Surrozen. Surrozen's average media sentiment score of 1.89 beat Aptose Biosciences' score of 0.72 indicating that Surrozen is being referred to more favorably in the news media.

Company Overall Sentiment
Aptose Biosciences Positive
Surrozen Very Positive

Summary

Aptose Biosciences beats Surrozen on 8 of the 15 factors compared between the two stocks.


Get Aptose Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APTO vs. The Competition

MetricAptose BiosciencesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$28.70M$2.70B$4.95B$7.48B
Dividend YieldN/A2.37%2.87%3.87%
P/E Ratio-0.2319.89203.6714.99
Price / SalesN/A230.562,922.9266.71
Price / CashN/A29.1894.4854.64
Price / Book0.304.244.454.67
Net Income-$41.82M-$6.09M$112.73M$211.02M
7 Day Performance2.62%5.10%4.92%2.90%
1 Month Performance-6.81%11.10%10.04%4.00%
1 Year Performance-79.08%11.05%12.55%8.23%

Aptose Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SRZN
Surrozen
1.7319 of 5 stars
$13.99
+17.9%
N/A-8.3%$28.54M$12.50M-0.8074Short Interest ↑
Positive News
FRLN
Freeline Therapeutics
3.0094 of 5 stars
$6.48
flat
$11.13
+71.7%
-15.6%$28.12MN/A-1.16152
NKGN
NKGen Biotech
0 of 5 stars
$1.26
-16.0%
N/AN/A$27.58MN/A0.00N/AUpcoming Earnings
Gap Up
ENTX
Entera Bio
1.9489 of 5 stars
$1.07
+1.9%
$10.00
+834.6%
+47.0%$30.82M$130,000.00-3.1519Short Interest ↑
Gap Up
SABS
SAB Biotherapeutics
3.2233 of 5 stars
$5.24
-4.6%
$10.00
+90.8%
+511.6%$27.42M$23.90M0.0056Upcoming Earnings
News Coverage
Gap Up
PLUR
Pluri
0 of 5 stars
$0.78
-6.0%
N/A-28.6%$32.35M$357,000.00-1.34123Short Interest ↓
News Coverage
INKT
MiNK Therapeutics
3.0956 of 5 stars
$0.94
+2.2%
$6.50
+592.3%
-52.4%$32.41MN/A-1.2937Short Interest ↓
Negative News
Gap Up
INAB
IN8bio
3.3331 of 5 stars
$1.05
-6.3%
$11.00
+952.6%
-24.3%$33.43MN/A-0.9331Short Interest ↓
ZIVO
ZIVO Bioscience
0 of 5 stars
$8.20
+2.5%
N/A-59.7%$22.63MN/A0.008Gap Up
AIM
AIM ImmunoTech
0 of 5 stars
$0.42
+10.5%
N/A-16.5%$20.51M$140,000.00-0.9822Gap Up

Related Companies and Tools

This page (NASDAQ:APTO) was last updated on 2/29/2024 by MarketBeat.com Staff